secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2026-07-28T11:33:48+00:00
Accession:  0001730430-26-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q2 ARCALYST revenue $243.6M (+55% YoY); raises FY2026 guidance to $980-995M
--------------------------------------------------------------------------------

- ARCALYST net product revenue $243.6M in Q2 2026, ~55% YoY growth; ~21% of 14,000 multiple-recurrence patients on therapy.
- 2026 ARCALYST net revenue guidance raised to $980-995M from prior $930-945M.
- Net income $25.4M vs $17.8M in Q2 2025; cash $525.9M, no debt.
- KPL-387 Phase 2 data: median time to treatment response 4.0 days at 300 mg SC monthly; Phase 3 PASTORALE enrolling.
- KPL-1161 preclinical; Phase 1 expected by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/0001730430-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/knsa-20260728x8k.htm
  HTML page:      https://secwatch.observer/filing/0001730430-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer